Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program.
Martin UnverdorbenChristian von HeymannAmparao SantamariaManish SaxenaThomas VanasscheRobert WilkinsJames JinCathy ChenPaolo ColonnaPublished in: Pacing and clinical electrophysiology : PACE (2021)
The periprocedural complication risk for edoxaban treated patients undergoing pacemaker or invasive cardiac monitoring implantation was low. This population of patients was well managed in routine practice. This article is protected by copyright. All rights reserved.
Keyphrases
- patients undergoing
- end stage renal disease
- newly diagnosed
- left ventricular
- venous thromboembolism
- ejection fraction
- atrial fibrillation
- quality improvement
- chronic kidney disease
- healthcare
- primary care
- vena cava
- coronary artery disease
- clinical practice
- patient reported outcomes
- heart failure
- adipose tissue
- insulin resistance
- type diabetes
- human health
- glycemic control
- weight loss
- inferior vena cava